Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma

Advances in Experimental Medicine and Biology

Volumn 746, Issue , 2012, Pages 95-108

  Ursu, Renata ^a   Carpentier, Antoine F ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1018 ISS; AGATOLIMOD; BACTERIAL DNA; CANCER ANTIBODY; CETUXIMAB; CPG 28; CPG OLIGODEOXYNUCLEOTIDE; IBRITUMOMAB TIUXETAN; IMO 2055; IRINOTECAN; RITUXIMAB; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CHEMORADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CPG MOTIF; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DNA STRUCTURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; MYALGIA; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SEPSIS; SJOEGREN SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR REJECTION; WEGENER GRANULOMATOSIS;

ADJUVANTS, IMMUNOLOGIC; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CPG ISLANDS; CYTOKINES; GLIOMA; HUMANS; IMMUNITY, INNATE; OLIGODEOXYRIBONUCLEOTIDES; SURVIVAL ANALYSIS;

BACTERIA (MICROORGANISMS);

EID: 84863000097     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3146-6_8     Document Type: Article

References (71)

1. Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization and antitumor activity. J Natl Cancer Inst 1984; 72:955-962. (Pubitemid 14131740)
2. Kuramoto E, Watanabe N, Iwata D et al. Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol 1992; 14:773-782.
3. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-549.
4. Zhao Q, Temsamani J, Iadarola PL et al. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996; 51:173-182. (Pubitemid 26018763)
5. Cornélie S, Hoebeke J, Schacht AM et al. Direct evidence that toll-like receptor (TRL9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif regognition. J Biol Chem 2004; 279(15):15124-15129. (Pubitemid 38618907)
6. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397. (Pubitemid 27334820)
7. Leifer CA, Kennedy MN, Mazzoni A et al. TRL9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 2004; 173(2):1179-1183. (Pubitemid 38924294)
8. Latz E, Verma A, Visintin A et al. Ligang-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007; 8(7):772-779. (Pubitemid 46965353)
9. Hornung V, Rothenfusser S, Britsch S et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-4537. (Pubitemid 34441357)
10. Henault M, Lee LN, Evans GF et al. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. J Immunol Methods 2005; 300:93-99. (Pubitemid 40805590)
11. Jego G, Bataille R, Geffroy-Luseau A et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-Like receptors. Leukemia 2006; 20(6):1130-1137. (Pubitemid 43797308)
12. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61(3): 195-204.
13. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-760. (Pubitemid 34293438)
14. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996; 157:2116-2122. (Pubitemid 126449689)
15. Klinman DM, Yi AK, Beaucage SL et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879-2883. (Pubitemid 26116242)
16. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28:2045-2054. (Pubitemid 28271721)
17. Cho HJ, Takabayashi K, Cheng PM et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18:509-514. (Pubitemid 30313954)
18. Klinman DM, Verthelyi D, Takeshita F et al. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity 1999; 11:123-129. (Pubitemid 29428805)
19. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-2559. (Pubitemid 28136702)
20. Vollmer J, Weeranta R, Payette P et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34(1):251-262. (Pubitemid 38111541)
21. Hartmann G, Weeratna RD, Ballas ZK et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164:1617-1624. (Pubitemid 30067282)
22. Bauer S, Kirschning CJ, Hacker H et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci 2001; 98:9237-9242. (Pubitemid 32743900)
23. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 2003; 8:115-127.
24. Dix AR, Brooks WH, Roszman TL et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999; 100:216-232. (Pubitemid 30038255)
25. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66(6):3294-3302.
26. El Andaloussi A, Sonabend AM, Han Y et al. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006; 54:526-535. (Pubitemid 44449333)
27. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949. (Pubitemid 39273735)
28. Golgher D, Jones E, Powrie F et al. Depletion of CD25 regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002; 32:3267-3275. (Pubitemid 35414884)
29. Carpentier AF, Chen L, Maltonti F et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59:5429-5432. (Pubitemid 29526450)
30. Auf G, Carpentier AF, Chen L et al. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7:3540-3543. (Pubitemid 33069992)
31. Carpentier AF, Xie J, Mokhtari K et al. Successful treatment of intracranial gliomas in at by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6:2469-2473. (Pubitemid 30399217)
32. Grauer OM, Molling JW, Bennink E et al. TRL ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008; 181(10):6720-6729.
33. Ilvesaro JM, Merrell MA, Li L et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 2008; 6(10):1534-1543.
34. Kawarada Y, Ganss R, Garbi N et al. NK- and CD (-) T-cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167(9):5247-5253. (Pubitemid 33009762)
35. Wooldridge JE, Ballas Z, Krieg AM et al. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89(9):2994-2998. (Pubitemid 27172587)
36. Takeshita S, Takeshita F, Haddad DE et al. Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport 2001; 12:3029-3032. (Pubitemid 32906999)
37. Meng Y, Kujas M, Marie Y et al. Expression of TLR9 within human glioblastoma. J Neurooncol 2008; 88:19-25.
38. Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of CpG ODN for patients with recurrent glioblastoma. Neurol Oncol 2006; 8(1):60-66. (Pubitemid 43154452)
39. Gupta K, Cooper C. A review if the role of CpG oligodeoxynucleotides as toll-like 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008; 9(3):137-145. (Pubitemid 351651997)
40. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007; 35(Pt 6):1461-1467.
41. Manegold C, Gravenor D, Woytowitz D et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26(24):3979-3986.
42. Readett DRJ, DenisL, Krieg AM et al. PF-3512676 (CPG 7909), a Toll-like receptor 9 agonist-status of development for nonsmall cell lung cancer (NSCLC).(abstract) 12th World Congress on Lung Cancer 2007; 2-6; Seoul, Korea, PD3-1-6.
43. Carson AK, Grossman SA, Fisher JD et al. Prognostic factors for survival in adult with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS Consortium phase I and II clinical trials. J Clin Oncol 2007; 25:2601-2606. (Pubitemid 47041234)
44. Friedman EJ. Immune modulation by ionizing radiation and implications for cancer immunotherapy. Curr Pharm Des 2002; 8(19):1765-1780. (Pubitemid 34846202)
45. Meng Y, Carpentier AF, Chen L et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005; 116(6):992-997. (Pubitemid 41209208)
46. Mason KA, Ariga H, Neal R et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11(1):361-369. (Pubitemid 40075816)
47. Milas L, Mason KA, Ariga H et al. CpG oligonucleotide enhances tumor response to radiation. Cancer Res 2004; 64(15):5074-5077. (Pubitemid 39006521)
48. Weigel BJ, Rodeberg DA, Krieg AM et al. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9(8):3105-3114. (Pubitemid 36993273)
49. Balsari A, Tortoreto M, Besusso D et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumor xenografts. Eur J Cancer 2004; 40(8):1275-1281. (Pubitemid 38526349)
50. Pratesi G, Petrangolini G, Tortoreto M et al. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an oythotopic human pancreatic carcinoma xenograft. Cancer Res 2005; 65(14):6388-6393. (Pubitemid 40994426)
51. Roux S, Bernat C, Al-Sakere B et al. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 2008; 57:1291-1300.
52. Hiraoka K, Yamamoto S, Otsuru S et al. Enhanced tumor-specific long-term immunity of hemagglutinating (correction of hemaggluttinating) virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 2004; 173(77):4297-4307. (Pubitemid 39280657)
53. Chamoto K, Takeshima T, Wakita D et al. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immunoresistant lung carcinoma cells. Cancer Sci 2009; 100:934-939.
54. Wu A, Oh S, Gharagozlou S et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007; 30(8):789-797.
55. Speiser DE, Lienard D, Ruffer N et al. Rapid and strong human CD8-T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-746. (Pubitemid 40322250)
56. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T-cells through cross-priming. Proc Natl Acad Sci USA 2007; 104(21):8947-8952. (Pubitemid 47175417)
57. Germeau C, Ma W, Schiavetti F et al. High frequency of antitumor T-cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005; 201(2):241-248. (Pubitemid 40189433)
58. Warren TL, Dahle CE, WeinerGJ. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000; 1:57-61.
59. Leonard JP, Link BK, Emmanouilides C et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkins lymphoma. Clin Cancer Res 2007; 13(20):6168-6174. (Pubitemid 350075077)
60. Hofmann MA, Kors C, Audring H et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31(5):520-527.
61. Pashenkov M, Goss G, Wagner C et al. Phase II trial of a toll-like receptor 9 oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24:5716-5724. (Pubitemid 46631314)
62. Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkins lymphoma. J Immunother 2006; 29(5):558-568. (Pubitemid 44395280)
63. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 2002; 169(5):2781-2787. (Pubitemid 34921028)
64. Krieg AM, Vollmer J. Toll-like receptors 7, 8 and 9 linking innate immunity to autoimmunity. Immunol Rev 2007; 220:251-269. (Pubitemid 350045572)
65. Cooper CL, Davis HL, Morris ML et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004; 22:3136-3143. (Pubitemid 39043651)
66. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-484. (Pubitemid 44136959)
67. Molenkamp BG, van Leeuwen PA, Meijer S et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007; 13(10):2961-2969. (Pubitemid 46849571)
68. Kim Y, Girardi M, McAuley S et al. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study. J Clin Oncol 2004; 22:582s (suppl; abstr 6600).
69. Thompson JA, Kuxel T, Bukowski F et al. Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). J Clin Oncol 2004; 22:417s (suppl; abstr 4644).
70. Wagner S, Weber J, Redman B et al. CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC (abstract). Proc Am Soc Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 23:7526.
71. Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin Lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105(2):489-495. (Pubitemid 40070726)